Table 2.
Multivariable analysis of COVID-19 patients with infections by multidrug-resistant organisms in Hong Kong West Cluster
| Adjusted odds ratio for COVID-19 patients with infections by MDROsa |
P Value | |
|---|---|---|
| Age | 1.015 (1.006–1.025) | 0.001 |
| Male sex | 1.597 (1.205–2.118) | 0.001 |
| Referral from RCHE | 2.891 (2.137–3.910) | < 0.001 |
| Charlson comorbidity index | 1.005 (0.935–1.081) | 0.892 |
| Presence of indwelling device | 3.339 (2.517–4.429) | < 0.001 |
| Presence of endotracheal tube | 3.880 (2.206–6.824) | < 0.001 |
| Use of corticosteroids as COVID-19 therapy | 0.798 (0.580–1.098) | 0.166 |
| Use of antimicrobial agents in the past 3 months | ||
| Carbapenems | 1.926 (1.345–2.8760) | < 0.001 |
| Cephalosporins | 1.128 (0.684–1.861) | 0.637 |
| BLBI | 1.419 (1.037–1.942) | 0.029 |
| Fluoroquinolones | 1.331 (0.787–2.253) | 0.286 |
| Use of proton pump inhibitors in the past 3 months | 1.653 (1.207–2.265) | 0.002 |
| History of hospitalization in the past 3 months | 1.429 (1.058–1.929) | 0.020 |
Note. BLBI, extended-spectrum beta-lactam-beta-lactamase inhibitor combinations; MDROs, multidrug-resistant organisms; RCHE, residential care home for the elderly; SD, standard deviation.
a
Based on multivariable logistic regression.